Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen ( EBV-EA ) activation with an IC 50 of 290 mol ratio/32 pmol TPA. Methyl lucidenate D exerts potential anti-tumor promoting activity by inhibiting TPA-induced EBV-EA activation and maintains major Raji cell survival (70%) at effective concentrations. Methyl lucidenate D can be used in the field of cancer chemoprevention.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > EBV
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.